-
Sam Bankman-Fried Appeals For ADHD Medication During Fraud Trial To 'Meaningfully Participate' In Defense
Sunday, October 15, 2023 - 11:56pm | 734Read More...In the latest development of the criminal trial against FTX co-founder Sam Bankman-Fried, his legal team has sought court permission for their client to use ADHD medication during the trial to better focus. What Happened: As reported by Cointelegraph on Sunday, Bankman-Fried’s attorneys have...
-
Elon Musk Sounds Off On Adderall's Effects: Here's What The Billionaire Has To Say
Sunday, May 7, 2023 - 10:23pm | 618Read More...Elon Musk shared his take on Adderall, a medication that is used to treat attention deficit hyperactivity disorder, or ADHD, on Sunday. What Happened: Musk said in response to a post on Twitter, "Adderall is an anger amplifier. Best used sparingly or not at all." Adderall is an anger amplifier....
-
Joe Rogan Calls Donald Trump 'Man Baby,' Asks If He Was On Adderall During Presidency
Tuesday, July 19, 2022 - 2:23am | 600Read More...Joe Rogan said on his podcast hosted on Spotify Technology SA’s (NYSE: SPOT) platform that former President Donald Trump is a “man-baby.” What Happened: Rogan’s comments came in conversation with the stand-up comedian and author Tom Segura. An excerpt from the podcast...
-
Why Elon Musk Says Psychedelics And Ketamine Are Better Than Pharma Meds
Saturday, April 30, 2022 - 2:51pm | 636Read More...Tesla Inc (NASDAQ: TSLA) CEO Elon Musk, the tech tycoon soon-to-become media tycoon who smoked a joint on a live stream video with Joe Rogan opined on Twitter Inc (NYSE: TWTR) on the effectiveness of psychedelics and other plant-based substances as treatments for mental health-...
-
Attention To Details: Neos' ADHD Portfolio
Monday, June 26, 2017 - 9:05am | 1269Read More...Neos Therapeutics Inc (NASDAQ: NEOS) shares began tumbling on June 20, despite announcing late on June 19 that the FDA approved its Cotempla XR-ODT, a methylphenidate extended-release orally disintegrating tablet for treating attention-deficit/hyperactivity disorder in patients aged 6–17...
-
KemPharm CEO On Recent Results, Catalysts And Prospects: 'ADHD Is By Far The Larger Market Opportunity'
Thursday, January 12, 2017 - 3:34pm | 855Read More...On Monday, KemPharm Inc (NASDAQ: KMPH) reported encouraging results from its exploratory Phase 1 study assessing the pharmacokinetics, safety and intranasal abuse potential of KP511 Active Pharmaceutical Ingredient, an investigational pain treatment prodrug. As per the analysis, KP511 demonstrated...
-
Shire Just Took Another Step Forward With Its ADHD Drug
Monday, April 4, 2016 - 5:05pm | 287Read More...BTIG's Timothy Chiang said Shire PLC (ADR) (NASDAQ: SHPG) moved one step closer to satisfying the FDA's request for clinical data with its SHP465 (a three-bead formulation of mixed amphetamine salts) compound for the treatment of ADHD (Attention-Deficit Hyperactivity Disorder). The...
-
UPDATE: Goldman Sachs Trims EPS Estimates for Impax Laboratories, Lowers PT
Friday, July 6, 2012 - 9:18am | 131Read More...In a research report published Friday morning, Goldman Sachs has lowered its EPS estimates for Impax Laboratories (NASDAQ: IPXL) to reflect the pharmaceutical company's supply agreement with Tolmar and changes in the Adderall XR market. According to Goldman Sachs, "While the impact from Actavis...
